2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Adverse Events, Biological Processes, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

3672 IND.244: A Canadian cancer trials group Phase 2 study of ibrutinib combination therapy in transplant ineligible individuals with newly diagnosed primary central nervous system lymphoma

Maria Florencia Comelles, Jean-Francois Larouche, MD2, Anca Prica, MD3, Diego Villa, MD4, Robert Puckrin, MD5, Kelly Davison, MD, PhD6, David Macdonald, MD7, Graeme Fraser, MD, MSc, FRCPC8, Abdulhakim Eswedi, FRCPC9, Andrew Cowan, MD10, Kerry Savage, MD, MSc, BSc11, Laurie H. Sehn, MD12, Carolyn Owen, MD13, Donatella Tampieri14, Omar Islam15, Jacob Rullo16, Todd Urton17, Nicole Mendonza18, Robert Kridel, MD19, Wei Tu20, Annette Hay, MBChB21
1 Queen's University, Kingston, Ontario, Canada
2 CHA-Hopital de l'Enfant-Jesus, Quebec, Quebec, Canada
3 UHN - Princess Margaret Cancer Centre, Toronto, Canada
4 BCCA - Vancouver Cancer Centre, Vancouver, Canada
5 Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Canada
6 The Research Institute of the McGill University Health Centre, Montreal, Canada
7 Ottawa Hospital Research Institute, Ottawa, Canada
8 Juravinski Cancer Centre at Hamilton Health Sciences Centre, Hamilton, Canada
9 Allan Blaire Cancer Centre, Regina, Canada
10 BCCA - Vancouver Cancer Centre, Vancouver, Canada
11 BCCA - Vancouver Cancer Centre, Vancouver, Canada
12 BCCA - Vancouver Cancer Centre, Vancouver, Canada
13 Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Canada
14 Kingston Health Sciences Centre, Kingston, Canada
15 Kingston Health Sciences Centre, Kingston, Canada
16 Kingston Health Sciences Centre, Kingston, Canada
17 Kingston Health Sciences Centre, Kingston, Canada
18 Queen's University, Kingston, Ontario, Canada
19 UHN - Princess Margaret Cancer Centre, Toronto, Canada
20 Queen's University, Kingston, Ontario, Canada
21 Queen's University, Kingston, Ontario, Canada

Background and significance: Primary CNS lymphoma (PCNSL) is an aggressive extranodal lymphoma with a median age at diagnosis of 60-70 years. Outcomes are particularly poor among patients ineligible for autologous stem cell transplant (ASCT), a population underrepresented in clinical trials. For these individuals, induction therapy typically consists of high-dose methotrexate alone or in combination with other agents, and consolidation is limited to radiotherapy, which is associated with high risk of neurotoxicity and suboptimal clinical outcomes.

The BTK inhibitor, ibrutinib, is active in relapsed PCNSL, in line with predominant activated B-cell cell-of-origin phenotype. Ibrutinib with methotrexate/rituximab has been evaluated in the relapsed/refractory setting and found to be safe with encouraging efficacy. These data support the evaluation of ibrutinib in addition to methotrexate and rituximab in patients with newly diagnosed, ASCT ineligible PCNSL, with the hypothesis that this combination will improve progression-free survival (PFS) while maintaining an acceptable safety and tolerability profile.

Study design and methods: The Canadian Cancer Trials Group IND.244 [NCT05998642] multi-centre, single arm, phase II trial is designed to evaluate ibrutinib, methotrexate with or without rituximab induction therapy, followed by ibrutinib consolidation, in patients with newly diagnosed PCNSL who are ineligible for stem cell transplant.

Eligibility criteria include i) patients aged ≥18 years with biopsy confirmed PCNSL including vitreo-retinal lymphoma or cerebrospinal fluid positive disease with lesions on MRI compatible with PCNSL, ii) patients considered ineligible for ASCT by the treating investigator due to older age and/or comorbidities and iii) Eastern Cooperative Oncology Group (ECOG) performance status of zero to two, or three if related to PCNSL and expected to improve. Patients are permitted to receive prior corticosteroids. Patients with clinically significant cardiac disease or anticoagulated with vitamin K antagonists are excluded. To facilitate enhanced accrual, the protocol was amended in September 2025 to permit enrollment of participants who have received a single cycle of methotrexate with or without rituximab as standard of care therapy.

Patients receive up to six induction cycles of 14 days. On day one, all participants receive methotrexate 3.5 g/m² IV. Additionally, rituximab 375 mg/m² IV (or 1400 mg SC for cycle two onward) is administered at centres where this aligns with local standard of care. Ibrutinib 560 mg is administered orally once daily on days 6–14. Following completion of induction, patients with a response or stable disease continue ibrutinib 560 mg PO daily as consolidation for a total of two years from study entry, with dose reductions permitted for toxicity.

The primary objective is one-year PFS. Secondary endpoints include response rate, one-year event-free survival, two-year PFS, overall survival, treatment safety and tolerability, patient-reported cognitive functioning and health related quality of life. Tertiary objectives include assessing plasma circulating tumor DNA and, when available, optional cerebrospinal fluid circulating tumor DNA, correlated with outcomes. The protocol incorporates centralized radiology and ophthalmology review.

Assuming a historical one-year PFS rate of 40% following methotrexate with or without rituximab, the study is powered to detect a 20% improvement with the addition of ibrutinib. A sample size of 28 patients with a one-sided α of 0.1 provides 80% power to detect a one-year PFS of 60%. We will enroll up to 30 patients in case of early drop outs.

As of June 2026, 20 participants have enrolled from eight sites across five Canadian provinces. The median age is 76 years-old (range 68-82). Participants self-identified as white (70%), Chinese (20%), or West Asian (10%). Regarding sex assigned at birth, 65% are male and 35% are female. The study incorporates an equity-focused design, including enrollment of non-English speakers, inclusion of people living with controlled HIV, patient partner engagement and prospective demographic data collection.

IND.244 is designed specifically for transplant ineligible older adults with PCNSL, seeking to improve disease control rates, while preserving cognitive function and quality of life. Supported by Janssen Inc.

Maria Florencia Comelles: No relevant conflicts of interest to declare.